학술논문
S204: SAFETY AND TOLERABILITY OF CAEL‐101, AN ANTI‐AMYLOID MONOCLONAL ANTIBODY, COMBINED WITH ANTI‐PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT‐CHAIN AMYLOIDOSIS: 18‐MONTH RESULTS OF A PHASE 2 STUDY.
Document Type
Article
Author
Source
HemaSphere; 2023 Supplement 3, Vol. 7, p1-2, 2p
Subject
Language
ISSN
25729241